Literature DB >> 21953120

Antioxidant supplement use after breast cancer diagnosis and mortality in the Life After Cancer Epidemiology (LACE) cohort.

Heather Greenlee1, Marilyn L Kwan, Lawrence H Kushi, Jun Song, Adrienne Castillo, Erin Weltzien, Charles P Quesenberry, Bette J Caan.   

Abstract

BACKGROUND: There is concern that antioxidant supplement use during chemotherapy and radiation therapy may decrease treatment effects, yet the effects of such supplements on recurrence and survival are largely unknown.
METHODS: The authors prospectively examined the associations between antioxidant use after breast cancer (BC) diagnosis and BC outcomes in 2264 women in the Life After Cancer Epidemiology (LACE) cohort. The cohort included women who were diagnosed with early stage, primary BC from 1997 to 2000 who enrolled, on average, 2 years postdiagnosis. Baseline data were collected on antioxidant supplement use since diagnosis and other factors. BC recurrence and mortality were ascertained, and hazard ratios (HRs) and 95% confidence intervals (CIs) were estimated using delayed entry Cox proportional hazards models. All tests of statistical significance were 2-sided.
RESULTS: Antioxidant supplement use after diagnosis was reported by 81% of women. Among antioxidant users, frequent use of vitamin C and vitamin E was associated with a decreased risk of BC recurrence (vitamin C: HR, 0.73; 95% CI, 0.55-0.97; vitamin E: HR, 0.71; 95% CI, 0.54-0.94); and vitamin E use was associated with a decreased risk of all-cause mortality (HR, 0.76; 95% CI, 0.58-1.00). Conversely, frequent use of combination carotenoids was associated with increased risk of death from BC (HR, 2.07; 95% CI, 1.21-3.56) and all-cause mortality (HR, 1.75; 95% CI, 1.13-2.71).
CONCLUSIONS: Frequent use of vitamin C and vitamin E in the period after BC diagnosis was associated with a decreased likelihood of recurrence, whereas frequent use of combination carotenoids was associated with increased mortality. The effects of antioxidant supplement use after diagnosis likely differ by type of antioxidant.
Copyright © 2011 American Cancer Society.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21953120      PMCID: PMC3323673          DOI: 10.1002/cncr.26526

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  19 in total

1.  An approach to several problems in using large databases for population-based case-control studies of the therapeutic efficacy and safety of anti-hypertensive medicines.

Authors:  B M Psaty; T D Koepsell; D Siscovick; P Wahl; J P Logerfo; T S Inui; E H Wagner
Journal:  Stat Med       Date:  1991-04       Impact factor: 2.373

2.  A randomized trial of antioxidant vitamins to prevent second primary cancers in head and neck cancer patients.

Authors:  Isabelle Bairati; François Meyer; Michel Gélinas; André Fortin; Abdenour Nabid; François Brochet; Jean-Philippe Mercier; Bernard Têtu; François Harel; Benoît Mâsse; Eric Vigneault; Sylvie Vass; Pierre del Vecchio; Jean Roy
Journal:  J Natl Cancer Inst       Date:  2005-04-06       Impact factor: 13.506

Review 3.  Should supplemental antioxidant administration be avoided during chemotherapy and radiation therapy?

Authors:  Brian D Lawenda; Kara M Kelly; Elena J Ladas; Stephen M Sagar; Andrew Vickers; Jeffrey B Blumberg
Journal:  J Natl Cancer Inst       Date:  2008-05-27       Impact factor: 13.506

4.  A new method of classifying prognostic comorbidity in longitudinal studies: development and validation.

Authors:  M E Charlson; P Pompei; K L Ales; C R MacKenzie
Journal:  J Chronic Dis       Date:  1987

Review 5.  Possible interactions between dietary antioxidants and chemotherapy.

Authors:  D Labriola; R Livingston
Journal:  Oncology (Williston Park)       Date:  1999-07       Impact factor: 2.990

6.  Life After Cancer Epidemiology (LACE) Study: a cohort of early stage breast cancer survivors (United States).

Authors:  Bette Caan; Barbara Sternfeld; Erica Gunderson; Ashley Coates; Charles Quesenberry; Martha L Slattery
Journal:  Cancer Causes Control       Date:  2005-06       Impact factor: 2.506

7.  The Beta-Carotene and Retinol Efficacy Trial: incidence of lung cancer and cardiovascular disease mortality during 6-year follow-up after stopping beta-carotene and retinol supplements.

Authors:  Gary E Goodman; Mark D Thornquist; John Balmes; Mark R Cullen; Frank L Meyskens; Gilbert S Omenn; Barbara Valanis; James H Williams
Journal:  J Natl Cancer Inst       Date:  2004-12-01       Impact factor: 13.506

8.  Incidence of cancer and mortality following alpha-tocopherol and beta-carotene supplementation: a postintervention follow-up.

Authors:  Jarmo Virtamo; Pirjo Pietinen; Jussi K Huttunen; Pasi Korhonen; Nea Malila; Mikko J Virtanen; Demetrius Albanes; Phil R Taylor; Paul Albert
Journal:  JAMA       Date:  2003-07-23       Impact factor: 56.272

9.  Ascorbic acid supplementation and five year survival rates in women with early breast cancer.

Authors:  J M Poulter; W F White; J W Dickerson
Journal:  Acta Vitaminol Enzymol       Date:  1984

10.  Partial and complete regression of breast cancer in patients in relation to dosage of coenzyme Q10.

Authors:  K Lockwood; S Moesgaard; K Folkers
Journal:  Biochem Biophys Res Commun       Date:  1994-03-30       Impact factor: 3.575

View more
  32 in total

1.  [Antioxidants and selenium should not be lumped together into one category-evaluation of supplementation during chemotherapy or radiotherapy for breast cancer].

Authors:  Marc D Piroth; Ralph Mücke; Oliver Micke
Journal:  Strahlenther Onkol       Date:  2019-09       Impact factor: 3.621

Review 2.  Mitochondrial ROS control of cancer.

Authors:  María Del Pilar Sosa Idelchik; Ulrike Begley; Thomas J Begley; J Andrés Melendez
Journal:  Semin Cancer Biol       Date:  2017-04-23       Impact factor: 15.707

3.  Metabolic shifts in residual breast cancer drive tumor recurrence.

Authors:  Kristina M Havas; Vladislava Milchevskaya; Ksenija Radic; Ashna Alladin; Eleni Kafkia; Marta Garcia; Jens Stolte; Bernd Klaus; Nicole Rotmensz; Toby J Gibson; Barbara Burwinkel; Andreas Schneeweiss; Giancarlo Pruneri; Kiran R Patil; Rocio Sotillo; Martin Jechlinger
Journal:  J Clin Invest       Date:  2017-05-15       Impact factor: 14.808

Review 4.  Effects of complementary and integrative medicine on cancer survivorship.

Authors:  Moshe Frenkel; Victor Sierpina; Kenneth Sapire
Journal:  Curr Oncol Rep       Date:  2015       Impact factor: 5.075

Review 5.  Redox Paradox: A Novel Approach to Therapeutics-Resistant Cancer.

Authors:  Luksana Chaiswing; William H St Clair; Daret K St Clair
Journal:  Antioxid Redox Signal       Date:  2018-02-21       Impact factor: 8.401

6.  Use of complementary and alternative medicine and breast cancer survival in the Health, Eating, Activity, and Lifestyle Study.

Authors:  Marian L Neuhouser; Ashley Wilder Smith; Stephanie M George; James T Gibson; Kathy B Baumgartner; Richard Baumgartner; Catherine Duggan; Leslie Bernstein; Anne McTiernan; Rachel Ballard
Journal:  Breast Cancer Res Treat       Date:  2016-10-21       Impact factor: 4.872

Review 7.  Anti-inflammatory/antioxidant use in long-term maintenance cancer therapy: a new therapeutic approach to disease progression and recurrence.

Authors:  Sarah Crawford
Journal:  Ther Adv Med Oncol       Date:  2014-03       Impact factor: 8.168

Review 8.  Nutritional countermeasures targeting reactive oxygen species in cancer: from mechanisms to biomarkers and clinical evidence.

Authors:  Anatoly Samoylenko; Jubayer Al Hossain; Daniela Mennerich; Sakari Kellokumpu; Jukka Kalervo Hiltunen; Thomas Kietzmann
Journal:  Antioxid Redox Signal       Date:  2013-04-15       Impact factor: 8.401

9.  Complementary and alternative medicine use and breast cancer prognosis: a pooled analysis of four population-based studies of breast cancer survivors.

Authors:  Rayna Kim Matsuno; Ian S Pagano; Gertraud Maskarinec; Brian F Issell; Carolyn C Gotay
Journal:  J Womens Health (Larchmt)       Date:  2012-10-17       Impact factor: 2.681

10.  Multivitamin and mineral use and breast cancer mortality in older women with invasive breast cancer in the women's health initiative.

Authors:  S Wassertheil-Smoller; A P McGinn; N Budrys; R Chlebowski; G Y Ho; K C Johnson; D S Lane; W Li; M L Neuhouser; J Saquib; J M Shikany; Y Song; C Thomson
Journal:  Breast Cancer Res Treat       Date:  2013-10-09       Impact factor: 4.872

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.